Thing is, blarcamesine (and 3-71 right behind it) are both pluripotent and applicable against multiple indications, so they’re not one trick ponies, but Renaissance Octopii.
All that seems to be very true. But one of the things that you are missing on is that although it is not data release, he has not started as far as we know any of the new trails that should be going and they were all to have happen before the end of last year. So right now, the new rare disease that we don’t know what it is yet is about eight months late along with the Parkinson’s trial , schizophrenia trial frontal lobe dementia I believe for 371 and anything else that out there. He has missed a lot with no explanations ever.
News 
Market Data 
Discover 
